Hyperbaric Chamber for Stroke Patients: Recovery & Treatment Guide
Explore the clinic directoryIn this article
- What is hyperbaric oxygen therapy for stroke?
- Does HBOT work for stroke recovery?
- Why does timing matter for HBOT after stroke?
- What does the research actually show for chronic stroke?
- What does the stroke HBOT protocol involve?
- How does HBOT compare with other stroke recovery treatments?
- Does insurance cover HBOT for stroke?
- How do I choose a stroke HBOT center?
- Who is a good candidate for HBOT after a stroke?
- Who should not try HBOT?
- Is hyperbaric oxygen therapy worth trying after a stroke?
- Frequently asked questions
- Sources
Hyperbaric oxygen therapy (HBOT) does not improve recovery when it is given during an acute stroke: a Cochrane review of 11 randomized trials and 705 patients found no significant benefit (Bennett et al., 2014).4 For chronic stroke the evidence is more encouraging. A 2013 Tel Aviv University randomized crossover trial of 74 patients found that 40 sessions at 2.0 ATA produced measurable neurological and cognitive gains 6 to 36 months after the event, changes confirmed on SPECT brain imaging, although that result comes from one research center and has not been replicated with a sham control.1
What this article covers
- HBOT does not help acute stroke: Bennett et al. (Cochrane, 2014) pooled 11 trials and 705 patients, and Li et al. (BMC Neurology, 2024) found no significant NIHSS difference across 8 trials and 493 patients.
- For chronic stroke, Efrati et al. (PLoS ONE, 2013) reported neurological, daily-living and quality-of-life gains after 40 sessions at 2.0 ATA in 74 patients who had plateaued 6 to 36 months after their stroke.
- Hadanny et al. (2020) found that 86% of 162 chronic-stroke patients reached a clinically significant cognitive improvement after 40 to 60 sessions, in a retrospective analysis with no control group.
- For post-stroke depression, Liang et al. (2020) pooled 27 trials and 2,250 patients and found a higher response rate with HBOT (69.4% versus 51.2%), while warning that trial quality was weak.
- Stroke is not among the 14 indications recognized by the Undersea and Hyperbaric Medical Society (UHMS), so HBOT for stroke is off-label and almost never covered by insurance.
- Middle-ear barotrauma is the most common side effect, reported in 17.4% of 2,334 patients by Hadanny et al. (2016), and an untreated collapsed lung rules treatment out.
Stroke recovery is not one of the 14 conditions the FDA and the Undersea and Hyperbaric Medical Society (UHMS) recognize for hyperbaric oxygen therapy, so any clinic offering it is working off-label.18 That does not make it worthless, but it does mean the evidence deserves a careful read. The research splits sharply by timing, and the protocol, the cost and the quality of the center matter as much as the headline findings. For the raw numbers behind these findings, see our HBOT stroke recovery statistics, and for the wider picture, our overview of HBOT for brain and neurological conditions.
What is hyperbaric oxygen therapy for stroke?
Hyperbaric oxygen therapy for stroke means breathing 100% oxygen inside a pressurized chamber, usually at 2.0 atmospheres absolute (ATA) in the stroke studies, to raise the amount of oxygen dissolved in the blood plasma. The treatment is also called HBOT, HBO2 therapy or hyperbaric oxygenation, and patients often search for it simply as a hyperbaric chamber for stroke recovery. Our guide to hyperbaric oxygen therapy covers the treatment itself across all of its uses.
Stroke, also called a cerebrovascular accident (CVA), comes in two main forms. An ischemic stroke is caused by a blocked artery, and a hemorrhagic stroke by bleeding into or around the brain. The chronic-stroke HBOT studies enrolled survivors of both types who were left with lasting deficits such as memory and attention problems, hemiparesis (weakness on one side), gait problems or aphasia (language difficulty).
In the research, HBOT is an add-on to rehabilitation and never a replacement for it. A typical team includes a neurologist, a hyperbaric medicine physician, a physiatrist (a rehabilitation physician), physical, occupational and speech-language therapists, and often a neuropsychologist who runs the cognitive testing that tracks progress.
Does HBOT work for stroke recovery?
HBOT does not work during the acute phase of a stroke, and it may help some survivors months or years later. During acute stroke, high-quality evidence shows no benefit. For chronic stroke, several small studies from a single Israeli research group report meaningful cognitive gains, and brain imaging supports the mechanism. The chronic-phase evidence is promising but has not been replicated independently with sham controls.

How is HBOT thought to work after a stroke?
The mechanism most often cited is the ischemic penumbra: a zone of stunned but still-living tissue surrounding the dead stroke core. Under normal conditions these cells sit metabolically dormant. HBOT delivers 100% oxygen at 2.0 ATA, dissolving far more oxygen into plasma than breathing air can, which may raise oxygen delivery to that marginal tissue enough to restart function.13 In the Efrati 2013 trial, SPECT imaging showed increased metabolic activity in previously dormant peri-infarct regions after 40 sessions, and that imaging change tracked with the clinical gains.1
Beyond simply flooding tissue with oxygen, laboratory work points to slower, regenerative effects. Hyperbaric oxygen mobilizes CD34+ bone-marrow stem cells through a nitric-oxide dependent pathway, roughly doubling circulating progenitor cells over a course of treatment.16 In rat stroke models, longer HBOT courses increased neurotrophic factor production, stem-cell migration to the injured brain, and reduced inflammation more than short courses.15 These pathways plausibly explain why the human protocol runs 40 sessions or more rather than a handful. Our page on HBOT and stroke neuroplasticity goes deeper on this mechanism.
Reviews of the stroke literature describe the same set of candidate mechanisms: hyperbaric oxygen maintains the viability of marginal penumbral tissue, reduces mitochondrial dysfunction, and blunts the inflammatory and reperfusion-injury cascades that follow ischemia.1314 In the chronic brain, the emphasis shifts from rescue to repair, with oxygen acting as a signal for angiogenesis, synaptogenesis, and the recruitment of stem and progenitor cells rather than as an emergency supply.12
Does better imaging mean better recovery?
The trade-off: mechanism is not outcome. A biologically plausible pathway and positive imaging do not prove that patients recover function they would not have recovered anyway, which is exactly why sham-controlled replication matters here. The same protocol has since been tested in a sham-controlled randomized trial for a different condition, post-COVID cognitive impairment, where it improved cognition and attention against a sham arm.19 That lends some external support to the idea that the effect is real rather than pure placebo, but it is not a substitute for a sham-controlled stroke trial, which still does not exist.
The same research group has applied the protocol to other brain injuries, and the evidence there has similar strengths and limits. Our pages on hyperbaric oxygen for brain injury and the traumatic brain injury condition guide cover that neighboring literature.
Why does timing matter for HBOT after stroke?
Timing is the single most important variable. Trials that treated patients during the acute phase, within hours to two weeks, found no significant benefit. Trials that treated chronic patients, at least three to six months out and plateaued in rehabilitation, are the ones reporting gains. The two bodies of evidence point in opposite directions.
What does the evidence say about HBOT for acute stroke?
For acute stroke, a Cochrane systematic review pooled 11 randomized controlled trials covering 705 patients and found no significant evidence that HBOT improves clinical outcomes.4 A 2024 meta-analysis in BMC Neurology reached the same conclusion across 8 trials and 493 patients, with no statistically significant difference in NIHSS stroke-severity scores (mean difference -1.41, 95% CI -7.41 to 4.58).5 An earlier systematic review by Carson and colleagues, funded to assess the evidence directly, likewise judged it insufficient to show benefit in any stroke subgroup.6 Standard acute care, thrombolysis and mechanical thrombectomy, remains the established treatment.
What changes in the chronic phase?
For chronic stroke the picture changes. In the Efrati 2013 crossover trial, 74 patients who had plateaued in recovery received 40 sessions at 2.0 ATA; the treated group showed significant improvement in neurological deficit, daily-living, and quality-of-life scores while the same patients had shown no change during a preceding two-month no-treatment control period.1 Why the acute-versus-chronic split exists is not fully settled, but the leading explanation is that acute injury involves active swelling, excitotoxicity, and reperfusion damage where extra oxygen may do little or even harm, whereas the chronic brain has stabilized and retains dormant tissue that oxygen and regenerative signaling might reactivate.12 Our detailed breakdown of HBOT timing after stroke and the case for treating chronic stroke years later cover this split in full.
In practical terms, a stroke survivor who is still in the first weeks after the event should be focused on emergency and early rehabilitation care. HBOT for stroke recovery only enters the conversation once recovery has leveled off, which in the published trials meant at least three months and often well over a year after the stroke.
What does the research actually show for chronic stroke?
The strongest chronic-stroke signal comes from Hadanny and colleagues, who retrospectively analyzed 162 patients treated at least three months after stroke. After 40 to 60 sessions at 2.0 ATA, 86% achieved a clinically significant cognitive improvement, defined as more than a half standard deviation gain in at least one domain, with statistically significant mean gains across every domain measured.2
Cognitive gains after HBOT in chronic stroke (Hadanny 2020, N=162)
| Cognitive domain | Mean change (points ± SD) | Significance | Source |
|---|---|---|---|
| Global cognitive score | +3.53 ± 7.68 | p < 0.0001 | Hadanny 2020 |
| Memory | +6.12 ± 15.46 | p < 0.0001 | Hadanny 2020 |
| Motor skills | +3.96 ± 14.27 | p = 0.001 | Hadanny 2020 |
| Executive function | +2.54 ± 10.37 | p = 0.003 | Hadanny 2020 |
| Information processing speed | +2.34 ± 9.28 | p = 0.005 | Hadanny 2020 |
| Attention | +2.95 ± 12.63 | p = 0.04 | Hadanny 2020 |
These are real measured changes, not before-and-after marketing figures. Two caveats belong next to them. First, this was a retrospective analysis with no control group, so some improvement could reflect practice effects, ongoing spontaneous recovery, or regression to the mean. Second, hemorrhagic strokes showed a larger gain in information processing speed than ischemic strokes (5.39 versus 1.36 points, p = 0.035), the only domain where stroke type mattered, which our page on HBOT for ischemic versus hemorrhagic stroke examines.2
A separate retrospective analysis of 91 chronic-stroke patients by Boussi-Gross and colleagues, using the same protocol, found statistically significant improvement across all memory measures.3 A small within-subject study by Rosario and colleagues (N=7) reported improved gait, executive function, sleep, and quality of life after 40 sessions.7 The consistency is encouraging, but nearly all of this positive chronic-stroke data traces to one research center, and a 2022 systematic review of 42 HBOT cognition studies concluded the field remains controversial and needs larger, better-controlled trials.8
HBOT for stroke: evidence by phase and outcome
| Phase / outcome | Best evidence (N) | Protocol | Result | Evidence grade |
|---|---|---|---|---|
| Acute stroke, functional recovery | Cochrane meta, 11 RCTs (705); Li 2024 meta, 8 trials (493) | Varied, started within days | No significant benefit | Strong evidence of no benefit |
| Chronic stroke, cognition | Efrati 2013 RCT (74); Hadanny 2020 (162); Boussi-Gross 2015 (91) | 40 to 60 sessions, 2.0 ATA, 90 min | Significant cognitive gains; 86% clinically significant improvement | Moderate, single-center |
| Chronic stroke, motor and daily function | Rosario 2018 (7); Efrati 2013 (74) | 40 sessions, 2.0 ATA | Improved gait, ADL and NIHSS in small samples | Emerging |
| Post-stroke depression | Liang 2020 meta, 27 RCTs (2,250); sham RCT 2026 (61) | 20 to 40 sessions, 2.0 ATA | Higher response rate (69.4% vs 51.2%), but low trial quality | Moderate |
It is worth being blunt about what “moderate, single-center” means. The Efrati crossover design is stronger than a simple before-and-after because each patient’s treated period is compared against their own untreated control period, which partly controls for spontaneous recovery. A crossover is still not a sham-controlled parallel trial: patients knew they were being treated, and some outcome measures are subjective or effort-dependent. When a treatment’s evidence base sits almost entirely inside one center’s patient population, independent replication is the missing piece, and until it arrives the honest label is promising, not proven.
Can HBOT help post-stroke depression?
Post-stroke depression is the one stroke-related outcome with pooled randomized evidence. A 2020 meta-analysis of 27 trials and 2,250 patients found a higher treatment response with HBOT than standard care (69.4% versus 51.2%, odds ratio 2.51), though the authors warned that the included trials were methodologically weak.10 A 2015 randomized trial found HBOT combined with fluoxetine outperformed either alone,9 and a 2026 randomized, sham-controlled trial in 61 patients linked HBOT to reduced depression scores and higher serum BDNF and beta-NGF.11
Depression after a stroke is common and treatable with standard care, including antidepressants and talk therapy. HBOT sits alongside those options as an adjunct, and our overview of depression treatment options covers the established and newer approaches, including transcranial magnetic stimulation (TMS).
What does the stroke HBOT protocol involve?
The protocol used in the chronic-stroke research is consistent: 40 to 60 daily sessions, five days a week, 90 minutes each, breathing 100% oxygen at 2.0 ATA in a hard-shell chamber. Soft-shell chambers cannot reach the pressure or oxygen concentration these studies used, so the research does not transfer to home units.
The chronic-stroke HBOT protocol at a glance
| Protocol element | What the stroke studies used |
|---|---|
| Pressure | 2.0 ATA |
| Breathing gas | 100% oxygen, often with short air breaks every 20 minutes |
| Session length | 90 minutes |
| Frequency | Five days a week |
| Total sessions | 40 to 60 |
| Course length | Roughly two to three months |
| Chamber type | Hard-shell chamber |
| Timing after stroke | At least three months; 6 to 36 months in Efrati 2013 |
| Measurement | Baseline and follow-up cognitive and functional testing |
Each session is undramatic. You lie or sit in the chamber while pressure rises over several minutes; ears pop as on an aircraft, which you manage by swallowing or yawning. At depth you breathe pure oxygen, often with short air breaks every 20 minutes to reduce oxygen-toxicity risk. Most patients read, listen to audio, or rest. Before starting, a good program establishes a baseline with cognitive and functional testing so progress can be measured against the numbers rather than impressions. Our guide to what to expect during HBOT walks through a first session in detail, and the Efrati protocol versus the Harch protocol compares the two main approaches.
Total course length matters. At five sessions a week, 40 to 60 sessions runs roughly two to three months of near-daily appointments, a real logistical and financial commitment that is worth weighing honestly before starting. The chronic-stroke studies did not test shorter courses, so a program advertising a quick 10-session package is not delivering the protocol the research supports.
HBOT is not a replacement for conventional rehabilitation. In the trials, patients continued physical, occupational, and speech therapy, and the researchers positioned oxygen as an adjunct that may widen the window for those therapies to work. See HBOT combined with physical therapy after stroke for how the two are sequenced.
Can a home or mild hyperbaric chamber help stroke recovery?
No published stroke trial supports a home or mild hyperbaric chamber. Every chronic-stroke study discussed here used a hard-shell chamber at 2.0 ATA with 100% oxygen, while soft-shell units run at lower pressure and usually deliver concentrated oxygen through a mask rather than a full medical oxygen environment. Our comparison of mild HBOT and clinical HBOT explains the differences in pressure, oxygen and supervision.
How does HBOT compare with other stroke recovery treatments?
HBOT is an off-label adjunct for chronic stroke, while clot-removing treatments and rehabilitation are the established core of stroke care. The table places hyperbaric oxygen therapy next to the treatments a stroke survivor is most likely to hear about, by phase and by the strength of the evidence behind each.
| Treatment | Stroke phase | What it does | Evidence and status |
|---|---|---|---|
| Thrombolysis (clot-dissolving drugs such as alteplase or tenecteplase) | Acute, within hours of an ischemic stroke | Restores blood flow through a blocked artery | Established emergency treatment |
| Mechanical thrombectomy | Acute, ischemic stroke from a large-vessel blockage | Removes the clot with a catheter | Established emergency treatment |
| Physical, occupational and speech therapy | Early and chronic | Retrains movement, daily tasks, language and swallowing | Core of stroke rehabilitation |
| Normobaric oxygen (supplemental oxygen at normal pressure) | Acute | Corrects low blood oxygen levels | Used when oxygen levels are low, not as a recovery therapy |
| Vagus nerve stimulation paired with rehabilitation | Chronic ischemic stroke with arm weakness | An implanted stimulator timed to rehabilitation exercises | FDA-approved device for this use |
| Transcranial magnetic stimulation (TMS) | Chronic | Noninvasive magnetic stimulation of the motor or language areas | Studied as an adjunct, not standard care for stroke |
| Hyperbaric oxygen therapy (HBOT) | Chronic, at least three months after stroke | 100% oxygen at 2.0 ATA for 40 to 60 sessions | Off-label; promising single-center evidence, no benefit in acute stroke |
Oxygen at normal pressure and oxygen under pressure are different treatments with different evidence. Our article on oxygen therapy for stroke covers supplemental oxygen in the hospital, and the comparison of HBOT and normobaric oxygen therapy explains why the pressure changes how much oxygen reaches tissue.
Does insurance cover HBOT for stroke?
Almost never. Because stroke recovery is not among the 14 FDA-cleared and UHMS-recognized indications, insurers classify HBOT for stroke as off-label and experimental, and routinely deny it.18 Medicare's national coverage policy for hyperbaric oxygen lists specific conditions, and stroke is not one of them. Plan on paying out of pocket. Each session runs roughly $200 to $400, so a 40 to 60 session course typically costs $12,000 to $24,000.
Some hospital-based programs bill covered indications separately, and a minority of plans consider appeals with strong documentation, but neither is reliable. Ask any center for written pricing, whether they offer payment plans, and what their refund policy is if you stop early. Our page on HBOT stroke cost and insurance breaks down the numbers, and the FDA-cleared indications for HBOT lists exactly which conditions do qualify.
Pricing varies by region, chamber type and whether the program is hospital-based or independent, and our HBOT cost breakdown explains what drives the per-session price.
How do I choose a stroke HBOT center?
Choose on accreditation, honesty, and coordination. The center should use a hard-shell chamber at 2.0 ATA, employ trained hyperbaric staff, run genuine cognitive and functional baselines, and coordinate with your neurologist and therapists rather than working in isolation. Ideally the facility is UHMS-accredited.
Be skeptical of any center promising dramatic stroke reversal. The chronic-stroke evidence is promising but single-center and unreplicated, and a legitimate provider will say so. Watch for programs that skip baseline testing, push soft-shell home chambers for a 2.0 ATA protocol, or bundle unrelated add-ons. Because the same treatment carries real risks, confirm the center screens for contraindications (covered below) and has emergency procedures for the rare but serious complications any high-oxygen environment can produce. For side-effect rates, see our guide to hyperbaric chamber side effects. Comparable evidence-versus-hype tension exists across brain conditions, which our overview of HBOT for neurological conditions and the data on HBOT for TBI and concussion both address.
What should I ask an HBOT center before starting?
- Who supervises the treatment? Ask whether a physician trained in undersea and hyperbaric medicine oversees each patient and whether a certified hyperbaric technologist runs the chamber.
- What pressure and chamber do you use? The stroke research used a hard-shell chamber at 2.0 ATA with 100% oxygen.
- How will you measure progress? Expect baseline and follow-up cognitive and functional testing, not only a symptom questionnaire.
- Will you coordinate with my neurologist and therapists? HBOT in the trials ran alongside rehabilitation, not instead of it.
- What is the full price, in writing? Ask about the total course, payment plans and the refund policy if you stop early.
- How do you screen for contraindications? A careful center reviews your lungs, ears, seizure history and medications before the first session.
The directory of hyperbaric oxygen therapy clinics lets you compare centers by state and city, with hospital-based and independent programs side by side. Regenerated.com is free for patients, and listing order is not paid ranking. Featured slots are clearly labeled and capped, and Verified means a clinic has completed credential checks, not that it paid for placement. Inclusion in the directory is not an endorsement, so put the questions above to every center you contact. Our explainer on how Featured, Verified and organic listings differ sets out each label in full, and state pages such as HBOT clinics in New York and hyperbaric centers in Pennsylvania narrow the search.
Who is a good candidate for HBOT after a stroke?
The patients who improved in the chronic-stroke studies shared a profile: they were medically stable, at least three months past their stroke, and had stopped making progress in rehabilitation. People who match that profile and have no contraindications are the group the evidence actually describes.
- Timing: at least three to six months after the stroke, with Efrati 2013 enrolling patients 6 to 36 months out.1
- Recovery plateau: progress in standard rehabilitation has leveled off.
- Measurable deficits: cognitive, memory, motor or daily-living problems that can be tested before and after treatment.
- Medical stability: no active cardiac, lung or seizure problem that makes pressurized oxygen unsafe.
- Ability to commit: two to three months of near-daily sessions and the out-of-pocket cost.
Survivors with mainly emotional symptoms, such as post-stroke depression, have a separate and somewhat stronger body of evidence, covered in the research section above. A neurologist or physiatrist who knows your history is the right person to weigh whether you fit this profile.
Who should not try HBOT?
HBOT is generally safe under trained supervision, but it is not for everyone. In a retrospective safety analysis of 2,334 patients, middle-ear barotrauma occurred in 17.4% of patients, while more serious events including oxygen toxicity, hypoglycemia, and anxiety reactions each occurred in only 0.5% to 1.5%.17 The main absolute barrier is an untreated pneumothorax.
Absolute contraindications
- Untreated pneumothorax (collapsed lung). Pressure changes can expand trapped air and become life-threatening.
- Certain chemotherapy agents. Bleomycin, cisplatin, doxorubicin, and disulfiram can interact dangerously with high-oxygen environments.
Relative contraindications (proceed only with medical clearance)
- Upper respiratory infection or sinus congestion, which makes ear and sinus equalization difficult and raises barotrauma risk.
- Seizure disorder, because high-pressure oxygen can lower the seizure threshold.
- COPD with carbon dioxide retention, which may need a modified protocol.
- High fever, which raises oxygen-toxicity risk.
- Previous ear surgery or chronic ear disease, where equalization may be unsafe.
- Claustrophobia, which may require a multiplace chamber or coaching. See managing claustrophobia in a hyperbaric chamber.
- Pregnancy, given insufficient safety data for routine use.
Tell your provider your full medication list and history before starting, especially if you use insulin (blood sugar can fall during sessions), have a pacemaker or implanted device, or take any of the drugs above. For the full clinical picture, see our HBOT research and evidence hub.
Seizures after a stroke deserve particular attention, because a stroke itself raises seizure risk and oxygen at pressure can lower the seizure threshold. Anyone with post-stroke seizures should have them reviewed by their neurologist before a hyperbaric center accepts them.
Is hyperbaric oxygen therapy worth trying after a stroke?
Hyperbaric oxygen therapy is not worth trying in the acute phase of a stroke, where pooled trials show no benefit. For a chronic stroke survivor who has plateaued in rehabilitation, it is a reasonable option to discuss with a neurologist, provided the expectations match the evidence: cognitive gains in single-center studies, no sham-controlled stroke trial yet, and a course of 40 to 60 sessions that is usually paid out of pocket.
The strongest case is for someone with measurable cognitive deficits who can commit to the full protocol at an accredited center that tests before and after treatment. The weakest case is a short package, a soft-shell chamber, or any program that presents HBOT as a replacement for rehabilitation.
Frequently asked questions
How soon after a stroke can I start HBOT?
The positive studies started HBOT at least three to six months after a stroke, once rehabilitation had plateaued. A Cochrane review of 11 trials found no benefit in the acute phase,4 and Efrati’s 2013 study enrolled patients 6 to 36 months post-stroke.1 You should be medically stable before starting, and the timing is a decision to make with your neurologist rather than with a chamber operator.
Does HBOT work for both ischemic and hemorrhagic stroke?
Yes, the chronic-stroke studies included both types, with similar overall improvement rates. In Hadanny’s 162-patient analysis, the only domain that differed by stroke type was information processing speed, where hemorrhagic strokes improved more than ischemic (5.39 versus 1.36 points, p = 0.035).2 Individual response still varies, and patients with more surviving penumbral tissue tend to respond better.
Is HBOT for stroke approved by the FDA?
No. Stroke recovery is not one of the 14 FDA-cleared and UHMS-recognized HBOT indications, so it is used off-label.18 Off-label use is legal and common in medicine, but it means the treatment has not cleared the regulatory bar for stroke. It also means insurers, including Medicare, almost never cover hyperbaric oxygen therapy for stroke recovery, so most patients pay out of pocket.
How many sessions does stroke HBOT require?
The chronic-stroke research used 40 to 60 daily sessions, five days a week, 90 minutes each at 2.0 ATA, which takes roughly two to three months.2 Shorter courses have not been shown to reproduce the cognitive gains, and animal work suggests longer courses drive more of the regenerative response.15 A center offering a handful of sessions is not following the studied protocol.
Can HBOT help with post-stroke depression?
Possibly, and the evidence here is more favorable than for physical recovery. A meta-analysis of 27 trials and 2,250 patients found a higher response rate with HBOT (69.4% versus 51.2%), and a 2026 sham-controlled trial linked it to lower depression scores and higher BDNF.1011 Trial quality is mixed, so treat it as a promising adjunct to standard depression care, not a replacement.
Sources
- Efrati S, Fishlev G, Bechor Y, et al. Hyperbaric oxygen induces late neuroplasticity in post stroke patients: randomized, prospective trial. PLoS ONE. 2013;8(1):e53716. doi:10.1371/journal.pone.0053716
- Hadanny A, Rittblat M, Bitterman M, et al. Hyperbaric oxygen therapy improves neurocognitive functions of post-stroke patients: a retrospective analysis. Restor Neurol Neurosci. 2020;38(1):93-107. doi:10.3233/RNN-190959
- Boussi-Gross R, Golan H, Volkov O, et al. Improvement of memory impairments in poststroke patients by hyperbaric oxygen therapy. Neuropsychology. 2015;29(4):610-621. doi:10.1037/neu0000149
- Bennett MH, Weibel S, Wasiak J, et al. Hyperbaric oxygen therapy for acute ischaemic stroke. Cochrane Database Syst Rev. 2014;(11):CD004954. doi:10.1002/14651858.CD004954.pub3
- Li X, Lu L, Min Y, et al. Efficacy and safety of hyperbaric oxygen therapy in acute ischaemic stroke: a systematic review and meta-analysis. BMC Neurol. 2024;24:55. doi:10.1186/s12883-024-03555-w
- Carson S, McDonagh M, Russman B, Helfand M. Hyperbaric oxygen therapy for stroke: a systematic review of the evidence. Clin Rehabil. 2005;19(8):819-833. doi:10.1191/0269215505cr907oa
- Rosario ER, Kaplan SE, Khonsari S, et al. The effect of hyperbaric oxygen therapy on functional impairments caused by ischemic stroke. Neurol Res Int. 2018;2018:3172679. doi:10.1155/2018/3172679
- Marcinkowska AB, Mankowska ND, Kot J, Winklewski PJ. Impact of hyperbaric oxygen therapy on cognitive functions: a systematic review. Neuropsychol Rev. 2022;32(1):99-126. doi:10.1007/s11065-021-09500-9
- Yan D, Shan J, Ze Y, Xiao-Yan Z, Xiao-Hua H. The effects of combined hyperbaric oxygen therapy on patients with post-stroke depression. J Phys Ther Sci. 2015;27(5):1295-1297. PMID:26157204
- Liang XX, Hao YG, Duan XM, Han XL, Cai XX. Hyperbaric oxygen therapy for post-stroke depression: a systematic review and meta-analysis. Clin Neurol Neurosurg. 2020;195:105910. PMID:32474256
- Hyperbaric oxygen therapy upregulates neurotrophic factors to ameliorate post-stroke depression: a randomized sham-controlled trial. Neuropsychiatr Dis Treat. 2026. doi:10.2147/NDT.S573494
- Efrati S, Ben-Jacob E. Reflections on the neurotherapeutic effects of hyperbaric oxygen. Expert Rev Neurother. 2014;14(3):233-236. doi:10.1586/14737175.2014.884928
- Sanchez EC. Mechanisms of action of hyperbaric oxygenation in stroke: a review. Crit Care Nurs Q. 2013;36(3):290-298. PMID:23736668
- Cozene B, Sadanandan N, Gonzales-Portillo B, et al. An extra breath of fresh air: hyperbaric oxygenation as a stroke therapeutic. Biomolecules. 2020;10(9):1279. doi:10.3390/biom10091279
- Lee YS, Chio CC, Chang CP, et al. Long course hyperbaric oxygen stimulates neurogenesis and attenuates inflammation after ischemic stroke. Mediators Inflamm. 2013;2013:512978. PMC3595722
- Thom SR, Bhopale VM, Velazquez OC, et al. Stem cell mobilization by hyperbaric oxygen. Am J Physiol Heart Circ Physiol. 2006;290(4):H1378-H1386. doi:10.1152/ajpheart.00888.2005
- Hadanny A, Meir O, Bechor Y, et al. The safety of hyperbaric oxygen treatment: retrospective analysis in 2,334 patients. Undersea Hyperb Med. 2016;43(2):113-122. PMID:27265988
- Undersea and Hyperbaric Medical Society. Hyperbaric oxygen therapy indications (approved UHMS indications). UHMS, 2023. uhms.org
- Zilberman-Itskovich S, Catalogna M, Sasson E, et al. Hyperbaric oxygen therapy improves neurocognitive functions and symptoms of post-COVID condition: randomized controlled trial. Sci Rep. 2022;12:11252. doi:10.1038/s41598-022-15565-0